Philip Gorelick, MD, MPH, FACP
John S. Garvin Professor and Head
Director, Center for Stroke Research
Department of Neurology and Rehabilitation
University of Illinois College of Medicine
Chicago, IL
Dr. Gorelick is the John S. Garvin Professor and Head, Department of Neurology and Rehabilitation, University of Illinois College of Medicine at Chicago (2003-present). Dr. Gorelick attended the Cardinal Stritch School of Medicine at Loyola and graduated in 1977. He completed Neurology Residency at Loyola and Hines VAH (1978-1981). After residency he served as a Stroke Fellow under Louis R. Caplan, MD, at Michael Reese Hospital as part of the University of Chicago Neurology Program (1981-1982). Dr. Gorelick then served as the Director of the University of Illinois Stroke Service in the Department of Neurology (1982-1985) where he received the Golden Apple and Alpha Omega Alpha awards for excellence in teaching. He was later the Director of the Stroke Service at Michael Reese Hospital (1985-1991) where he received the Langendorf Teaching Award from the Department of Medicine and was the Director of the Stroke and Neurological Critical Care Service at Rush Medical Center (1991-2003) where he was awarded an endowed chair in Neurology — the Jannotta Presidential Chair. Dr. Gorelick is board-certified in Neurology and Vascular Neurology.
Dr. Gorelick has received funding from the NIH since 1987 for such studies as the Afrcian American Antiplatelet Stroke Prevention Study, Risk Markers for Dementia After Stroke, and Neuroepidemiology of Multi-Infarct Dementia. His research focus has been identification of risk factors for stroke, first and recurrent stroke prevention, stroke prevention in high risk populations, and elucidating risk factors for vascular forms of cognitive impairment (VCI) and understanding mechanisms of VCI. Dr. Gorelick has received the Feinberg Award for Excellence in Clinical Stroke 2004 from the American Heart Association and the National Stroke Association (NSA) Visionary in Stroke Award. He has also held the Daniel Gainey Professorship 2005 at Mayo Clinic and the Henry Barnett 2005 Lectureship from the Canadian Stroke Network. Dr. Gorelick has been cited by Good Housekeeping as one of the top Stroke Neurologists in the United States and is a member of the Goddess Fund Stroke Advisory Board, Board of Directors of the NSA, and Advisory Board for the American Stroke Association.
Disclosure Statement
Governmental: NIH AG/NS17934 grant, NIH NS33430 grant
Speaker Bureaus/Honoraria: Janssen/Excerpta Medica, DuPont, Roche Laboratories, Bristol Myers-Squibb, Boehringer Ingelheim, Medical Economics
Consultant Agreements/Consultant Fees: NPS, Eisai/Pfizer, Searle/Lorex, Roche Laboratories, Ketchum, AstraZeneca, Glaxo Wellcome, Warner-Lambert, Baxter, Rand, Solvey Pharmaceuticals, Consumer Healthcare Products Association, Janssen, Res Med, Pharmacia, Novartis, Cephalon, Boehringer Ingelheim, Eli Lilly, Wyeth, Bayer, Merck, decode Genetics, and ALZA
Thought Leader Panel/Honoraria: Weinberg Group
Medication Supply for NIH NS33430: Roche Laboratories and Bayer
